Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

CONTEXT: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). AIMS: To evaluate the efficacy of intravesical chemotherapy (IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Serretta, Vincenzo, Sommatino, Francesco, Gesolfo, Cristina Scalici, Franco, Vito, Cicero, Giuseppe, Allegro, Rosalinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310111/
https://www.ncbi.nlm.nih.gov/pubmed/25657538
http://dx.doi.org/10.4103/0974-7796.148582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310111/
https://www.ncbi.nlm.nih.gov/pubmed/25657538
http://dx.doi.org/10.4103/0974-7796.148582

Ejemplares similares